[原创]肺癌患者有奇迹吗？

红叶舞

能在这见到热心的医生真好,这里需要您的帮助,大家一起努力!

tkmtt

请问：中医能治疗癌症吗，哪怕仅仅是控制住病情的发展？谢谢

jli999

    欢迎瘤吧医生的到来,我们这些苦难的患者和家属太需要专业的指导和帮助.恳请常来这里看看!

    再次对您的到来表示欢迎和敬意!

瘤吧

QUOTE:

以下是引用tkmtt在2007-7-22 1:08:53的发言：

请问：中医能治疗癌症吗，哪怕仅仅是控制住病情的发展？谢谢

目前的医学证据表明中医在癌症治疗中的作用不大，最多只起到减轻副反应和安慰的作用，不能提高生存期。

在各省市各大肿瘤医院的周边会遇到一波又一波鬼鬼祟祟派发神奇中药传单的人，美其名什么FDA批准，国家科技进步奖，国家主席召见，列出一大堆病人治愈的例子和图片，不断攻击传统手术放疗化疗的缺点，用一套中医辩证平衡的理论给你描绘美好的前景，具体的药名层出不穷。那些药贩子的目的只有一个：欺骗疾病乱投医的人，榨干你家里的最后一分钱，当苦难的癌症患者人财两空病情延误的时候哭都哭不出来。

无可厚非，传统的治疗目前也拿大多数癌症没办法，但它至少可以治愈一部分患者，每个理论疗效的提出都有严谨的文献可查。鉴别两者的一个方法是药贩子总是说得天花乱坠，而正规军总是客观的陈述事实，直面自身的不足，总是把坏话说在前头。但往往无知患者总是相信前者，以为这些所谓的中药会给他们带来一线生机。

细胞毒性药物中也不少含有中医的植物提取成分：如紫杉醇、三氧化二砷、羟基喜树碱等。中西医不是完全割裂的，传统中医药文化有其精髓所在，但目前在癌症治疗领域还没显示出来。是金子总要发光，中医药要真正造福于癌症患者还有很长的路，提供科学的药理、病理生理、循证医学证据。

瘤吧

QUOTE:

以下是引用jli999在2007-7-22 2:09:47的发言：

    欢迎瘤吧医生的到来,我们这些苦难的患者和家属太需要专业的指导和帮助.恳请常来这里看看!

    再次对您的到来表示欢迎和敬意!

try my best.

瘤吧

Erbitux 治疗肺癌待进一步评估并引起股票波动

??DXY 胭脂翻译
??
??周四早晨ImClone Systems公司和Bristol-Myers Squibb公司发表联合申明， 在一项三期临床试验中，联合Erbitux以及化疗药紫杉烷和卡铂进行抗体靶向治疗并未减缓晚期非小细胞肺癌生长。
??
??这项在加拿大和美国进行的临床试验，有600名患者参加，是几项专门为检验Erbitux对于肺癌疗效的临床试验之一。在这些临床试验中，检验Erbitux联合化疗药顺铂和长春瑞滨的临床试验是最大的一项，但是它的结果尚未得到。
??
??Erbitux是由ImClone Systems公司和Bristol-Myers Squibb公司联合推出的治疗结直肠癌的药物，也是ImClone唯一上市的药物。在海外它的名字为西妥昔单抗，由德国drugmaker Merck KGaA公司销售。自从2004年被核准用于治疗晚期直结肠癌后，Erbitux在2006年的销售额为11亿美元。其后此药也被核准治疗头、颈部癌症。为了扩展市场前景，Bristol-Myers and ImClone两家公司致力于证实Erbitux能够用于其它癌症，例如胰癌、肺癌的治疗。迄今为止临床试验的结果还是不明了。4月份，一项3期临床尝试将Erbitux与首选化疗药2,2-二氟脱氧胞嘧啶核苷联合治疗胰腺癌患者，结果显示Erbitux并不能延长患者的生命。
??
??尽管临床试验结果不好，ImClone and Bristol-Myers两家公司还是宣布会进一步检测Erbitux对于肺癌的疗效。Eric Rowinsky，ImClone's的首席医疗官员在申明中说，我们认为将之用于肺癌的治疗是我们的首选，我们等候着将Erbitux置于一线和二线并与化疗联合应用的临床2期和3期临床试验的结果。
??
??从当天的最低点33.57美金上扬后，在下午早些时候ImClone的股票总共下滑的5％。但是Bristol-Myers的投资者好像并没有受到影响，他们把Bristol-Myers的股票拉高了2％，达到32.11美金。
??

    分子预测势在必行！！！

    Erbitux found ineffective in lung-cancer study
??
??By Val Brickates Kennedy & Angela Moore, MarketWatch
??
??Erbitux, the colorectal cancer drug marketed by ImClone Systems Inc. and Bristol-Myers Squibb Co., is ineffective in slowing down the growth of lung-cancer tumors, results of a large-scale clinical trial show.
??
??In a statement released early Thursday, the companies said that a Phase III study testing Erbitux in combination with widely used chemotherapy drugs taxane and carboplatin showed the antibody-based therapy failed to slow the growth of tumors in patients with advanced non-small cell lung cancer, the most prevalent form of the highly lethal disease.
??
??The 600-patient study conducted in U.S. and Canada is one of several clinical trials designed to test the effectiveness of Erbitux in the treatment of lung cancer, the leading cause of cancer-related death in the U.S. Data from the largest of these studies, one which tests Erbitux in combination with the chemotherapy drugs cisplatin and vinorelbine, are not yet available. Erbitux, jointly marketed in North America by ImClone (IMCL : ImClone Systems Inc
??
??BMY, is ImClone's only marketed product. Known generically as cetuximab, it's distributed overseas by German drugmaker Merck KGaA (DE:659990: news, chart, profile) .
??Shares of ImClone dropped nearly 5% by early afternoon, recovering modestly from an intraday low at $33.57. Bristol-Myers investors, however, appeared unfazed, pushing up shares almost 2% to $32.11.
??
??Approved in February 2004 for the treatment of advanced colorectal cancer, Erbitux had 2006 sales of $1.1 billion. The drug was later approved to also treat head and neck cancers.
??
??In an effort to expand its market opportunities, Bristol-Myers and ImClone have been seeking to have Erbitux approved to treat other forms of cancer, such as pancreatic and lung cancer. Thus far, however, clinical trials have produced mixed results.
??
??In April, a Phase III clinical trial indicated that Erbitux was ineffective in extending the lives of patients with pancreatic cancer, an extremely deadly disease, when used in combination with a leading chemotherapy drug, gemcitabine.
??
??Despite the disappointing results released Thursday, ImClone and Bristol-Myers vowed to continue testing Erbitux in the treatment of lung cancer.
??
??"We consider lung cancer to be a high priority and await the results of other Phase II and Phase III evaluations of Erbitux in the first- and second-line setting with chemotherapy regimens," said Eric Rowinsky, ImClone's chief medical officer, in a statement.
??
??Val Brickates Kennedy is a reporter for MarketWatch in Boston.
??Angela Moore is MarketWatch's consumer editor based in New York.

[此贴子已经被作者于2007-7-22 10:08:50编辑过]

瘤吧

简评：继ISEL的失败，erbitux再次遭遇滑铁卢，分子预测势在必行，撒大网必败无疑。

[此贴子已经被作者于2007-7-22 10:19:32编辑过]

瘤吧

GSK将有5种治疗癌症新药投放市场

http://www.dxy.cn/bbs/post/view?bid=116&id=9334084&sty=1&tpg=1&age=0

关键词：肺癌疫苗 NEJM 文迪娅事件 股票

GSK to launch five new drugs to tackle cancer
By Karen Attwood
Published: 19 June 2007
GlaxoSmithKline, Europe's biggest drug-maker, is to launch five cancer drugs in the next three years as it increases its exposure to a lucrative £20bn market.

The company, which has taken a hit in recent weeks after its diabetes drug Avandia was linked to an increased risk of heart attacks, has also unveiled plans to enrol the first patients in its lung-cancer vaccine trial, which will begin in September. Glaxo is competing with Germany's Merck to produce the first lung-cancer vaccine and will commence the largest late-stage study of a treatment for the disease, which kills around 1.3 million people worldwide each year.

The five new oncology products set for launch by 2010 are the cervical cancer vaccine Cervarix; the renal cancer drug Pazopanib; Promacta, an oral compound to help cancer patients build up their platelet count and reduce bleeding; Rezonic, which helps to control symptoms associated with chemotherapy such as nausea; and Ofatumumab, an antibody to treat leukaemia which has blockbuster potential.

Glaxo's head of research and development, Moncef Slaoui, called the target "an unprecedented objective for a pharmaceutical company". He said Glaxo was developing late-stage medicines in more than 12 types of cancer and had a significant number of compounds in early-stage discovery.

Glaxo aims to establish itself as a major player in the oncology market, which is growing by 20 per cent annually.

Recent developments at Glaxo have been overshadowed by the furore surrounding Avandia. Shares have lost 10 per cent of their value since a study in the New England Journal of Medicine in May linked the drug, the firm's second best seller, to an increased risk of heart attack. Although Glaxo disputes the findings, sales and prescriptions of the drug have been hit. Analysts have remained positive on the stock owing to the potential of the pipeline and said the share price fall due to the Avandia scare will prove to be excessive.

Julien Dormois, health and life science analyst at Bryan Garnier, said Avandia remains a blockbuster and the impact of falling sales has already been priced in. He added: "It is becoming clearer and clearer that Glaxo may become the second major force for oncology worldwide behind Roche."

For Glaxo's lung cancer trial, 2,200 patients diagnosed with non-small cell lung cancer, the most common form of the disease, will be treated with the vaccine. It is hoped the vaccine may prevent the cancer from returning following surgery and will enable patients to live longer by helping their immune systems to recognise and destroy cancer cells. Lung cancer has one of the lowest survival rates, with 85 per cent of patients dying within five years.

丁香园anmb1编译：

GSK将5种治疗癌症新药投放市场

据英国《独立报》报道，欧洲最大的药品制造商——葛兰素史克公司，计划在未来三年内上市5种抗癌药物，以便在有利可图的200亿英镑的市场中扩大其份额。

2010年之前计划投放市场的抗癌药物是：子宫颈癌疫苗Cervarix、肾癌药物Pazopanib、有助于癌症患者提高血小板数量和减少出血的口服药物Promacta、有助于控制化疗引起的恶心等症状的药物Rezonic以及可能成为重磅药物的治疗白血病抗体Ofatumumab。

该公司研发部主管Moncef Slaoui声称，这一目标对于制药公司来说是史无前例的。他说，该公司针对超过12种类型癌症的治疗药物正处于后期开发阶段，还有大量的化合物处于早期研发阶段。葛兰素的目标是在年增长率为20%的肿瘤药物市场中扮演主要的角色。

在最近几周因其治疗糖尿病药物文迪雅涉嫌增加心脏病发作风险而受重挫的该公司，最近也已向外界透露了九月份开始的最大规模的一项肺癌疫苗后期临床研究计划，2200名诊断为非小细胞肺癌这一最常见的肺癌的患者将纳入该疫苗临床试验，而首例病人即将入组。葛兰素与德国默克公司竞争开发首个肺癌疫苗，该疫苗有望预防肺癌术后复发，并将通过帮助免疫系统识别和摧毁癌症细胞来延长患者生命。肺癌是存活率最低的癌症之一，85%的患者在5年内将离开人世。即据估计，每年全世界范围内约130万人死于肺癌。

葛兰素公司的近期发展因文迪雅事件而黯然失色。自5月份《新英格兰医学杂志》发表该药物（该公司第二大畅销药）与增加心脏病发作风险有关的文章以来，该公司股票已经下跌10%。尽管葛兰素对此提出抗议，但该药物销售量和处方量均受到打击。基于可能的渠道，分析家对其股票仍持正面评价，并称股票价值下跌原因是对文迪雅事件的过度恐惧。 Bryan Garnier投资公司健康和生命科学分析师Julien Dormois称，文迪雅仍然属于重磅炸弹级药物，销量下降的影响已被消化。他补充道，葛兰素继罗氏之后成为世界肿瘤药物市场第二大主力的迹象越来越明朗。

http://news.independent.co.uk/business/news/article2675849.ece
    

GSK将5种治疗癌症新药投放市场

据英国《独立报》报道，欧洲最大的药品制造商——葛兰素史克公司，计划在未来三年内上市5种抗癌药物，以便在有利可图的200亿英镑的市场中扩大其份额。

2010年之前计划投放市场的抗癌药物是：子宫颈癌疫苗Cervarix、肾癌药物Pazopanib、有助于癌症患者提高血小板数量和减少出血的口服药物Promacta、有助于控制化疗引起的恶心等症状的药物Rezonic以及可能成为重磅药物的治疗白血病抗体Ofatumumab。

该公司研发部主管Moncef Slaoui声称，这一目标对于制药公司来说是史无前例的。他说，该公司针对超过12种类型癌症的治疗药物正处于后期开发阶段，还有大量的化合物处于早期研发阶段。葛兰素的目标是在年增长率为20%的肿瘤药物市场中扮演主要的角色。

在最近几周因其治疗糖尿病药物文迪雅涉嫌增加心脏病发作风险而受重挫的该公司，最近也已向外界透露了九月份开始的最大规模的一项肺癌疫苗后期临床研究计划，2200名诊断为非小细胞肺癌这一最常见的肺癌的患者将纳入该疫苗临床试验，而首例病人即将入组。葛兰素与德国默克公司竞争开发首个肺癌疫苗，该疫苗有望预防肺癌术后复发，并将通过帮助免疫系统识别和摧毁癌症细胞来延长患者生命。肺癌是存活率最低的癌症之一，85%的患者在5年内将离开人世。即据估计，每年全世界范围内约130万人死于肺癌。

葛兰素公司的近期发展因文迪雅事件而黯然失色。自5月份《新英格兰医学杂志》发表该药物（该公司第二大畅销药）与增加心脏病发作风险有关的文章以来，该公司股票已经下跌10%。尽管葛兰素对此提出抗议，但该药物销售量和处方量均受到打击。基于可能的渠道，分析家对其股票仍持正面评价，并称股票价值下跌原因是对文迪雅事件的过度恐惧。 Bryan Garnier投资公司健康和生命科学分析师Julien Dormois称，文迪雅仍然属于重磅炸弹级药物，销量下降的影响已被消化。他补充道，葛兰素继罗氏之后成为世界肿瘤药物市场第二大主力的迹象越来越明朗。

http://news.independent.co.uk/business/news/article2675849.ece
    

  

[此贴子已经被作者于2007-7-22 11:21:59编辑过]